CHD5, a tumor suppressor that is epigenetically silenced in lung cancer

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 324-331

  Zhao, Rui ^a,b   Yan, Qitao ^b,c   Lv, Jingye ^a   Huang, Haili ^a   Zheng, Wenling ^a   Zhang, Bao ^a   Ma, Wenli ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangzhou Wang Cheong Adhesive Product Factory   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

CHD5; Epigenetic silenced; Hypermethylation; Lung cancer; Tumor suppressor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA HELICASES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 84858207248     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.019     Document Type: Article

References (24)

1. Thompson P.M., Gotoh T., Kok M., White P.S., Brodeur G.M. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003, 22:1002-1011.
2. Marfella C.G., Imbalzano A.N. The Chd family of chromatin remodelers. Mutat Res 2007, 618:30-40.
3. White P.S., Thompson P.M., Gotoh T., Okawa E.R., Igarashi J., Kok M., et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005, 24:2684-2694.
4. Brodeur G.M., Sekhon G., Goldstein M.N. Chromosomal aberrations in human neuroblastomas. Cancer 1977, 40:2256-2263.
5. White P.S., Maris J.M., Beltinger C., Sulman E., Marshall H.N., Fujimori M., et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA 1995, 92:5520-5524.
6. Piaskowski S., Rieske P., Szybka M., Wozniak K., Bednarek A., Pluciennik E., et al. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 2005, 162:63-67.
7. Poetsch M., Dittberner T., Woenckhaus C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 2003, 13:29-33.
8. Melendez B., Cuadros M., Robledo M., Rivas C., Fernandez-Piqueras J., Martinez-Delgado B., et al. Coincidental LOH regions in mouse and humans: evidence for novel tumor suppressor loci at 9q22-q34 in non-Hodgkin's lymphomas. Leuk Res 2003, 27:627-633.
9. Mori N., Morosetti R., Mizoguchi H., Koeffler H.P. Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br J Haematol 2003, 122:226-230.
10. Mori N., Morosetti R., Spira S., Lee S., Ben-Yehuda D., Schiller G., et al. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 1998, 92:3405-3409.
11. Bello M.J., Leone P.E., Vaquero J., de Campos J.M., Kusak M.E., Sarasa J.L., et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995, 64:207-210.
12. Moley J.F., Brother M.B., Fong C.T., White P.S., Baylin S.B., Nelkin B., et al. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 1992, 52:770-774.
13. Kleer C.G., Bryant B.R., Giordano T.J., Sobel M., Merino M.J. Genetic changes in chromosomes 1p and 17p in thyroid cancer progression. Endocr Pathol 2000, 11:137-143.
14. Praml C., Finke L.H., Herfarth C., Schlag P., Schwab M., Amler L. Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 1995, 11:1357-1362.
15. Cheung T.H., Lo K.W., Yim S.F., Poon C.S., Cheung A.Y., Chung T.K., et al. Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol Oncol 2005, 96:510-515.
16. Bieche I., Champeme M.H., Matifas F., Cropp C.S., Callahan R., Lidereau R. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 1993, 53:1990-1994.
17. Bagchi A., Papazoglu C., Wu Y., Capurso D., Brodt M., Francis D., et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475.
18. Mulero-Navarro S., Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 2008, 3:210-215.
19. Fujita T., Igarashi J., Okawa E.R., Gotoh T., Manne J., Kolla V., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949.
20. Gorringe K.L., Choong D.Y., Williams L.H., Ramakrishna M., Sridhar A., Qiu W., et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008, 10:1253-1258.
21. Wang X., Lau K.K., So L.K., Lam Y.W. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci 2009, 16:95.
22. Li L.C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-1431.
23. Bock C., Reither S., Mikeska T., Paulsen M., Walter J., Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005, 21:4067-4068.
24. Valk-Lingbeek M.E., Bruggeman S.W., van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004, 118:409-418.